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Background:  Inactivated  quadrivalent  inﬂuenza  vaccine  (IIV4)  containing  two  inﬂuenza  A  strains  and
one strain  from  each  B  lineage  (Yamagata  and  Victoria)  may  offer  broader  protection  against  seasonal
inﬂuenza  than  inactivated  trivalent  inﬂuenza  vaccine  (IIV3),  containing  a single  B strain.  This  study
examined  the  safety,  immunogenicity,  and  lot  consistency  of  an  IIV4  candidate.
Methods:  This  phase  III, randomized,  controlled,  multicenter  trial in children/adolescents  (9  through  17
years) and  adults  (18 through  60 years)  was  conducted  in  Australia  and  in the Philippines  in  2012. The
study  was double-blind  for IIV4  lots  and  open-label  for  IIV4  vs IIV3. Children/adolescents  were  ran-
domized  2:2:2:1  and adults 10:10:10:1  to receive  one  of three  lots  of  IIV4  or licensed  IIV3.  Safety  data
were  collected  for up  to 6  months  post-vaccination.  Hemagglutination  inhibition  and  seroneutralization
antibody  titers  were  assessed  pre-vaccination  and  21 days  post-vaccination.
Results:  1648  adults  and  329  children/adolescents  received  IIV4,  and 56 adults  and  55 chil-
dren/adolescents  received  IIV3.  Solicited  reactions,  unsolicited  adverse  events,  and  serious  adverse  events
were  similar  for IIV3 and  IIV4  recipients  in both  age  groups.  Injection-site  pain,  headache,  malaise,  and
myalgia  were  the  most  frequently  reported  solicited  reactions,  most  of  which  were  mild  and  resolved
within  3 days.  No  vaccine-related  serious  adverse  events  or  deaths  were  reported.  Post-vaccination  anti-
body  responses,  seroconversion  rates,  and  seroprotection  rates  for the  3 strains  common  to  both  vaccines
were  comparable  for IIV3 and  IIV4  in  both  age groups.  Antibody  responses  to  IIV4 were  equivalent  among
vaccine  lots  and  comparable  between  age  groups  for  each  of  the  4 strains.  IIV4  met all  European  Medicines
Agency  immunogenicity  criteria  for adults  for all 4 strains.
Conclusions:  In both  age  group
antibody  responses  to all 4 inﬂ
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. Introduction
Inactivated quadrivalent inﬂuenza vaccines (IIV4s) contain
nactivated split virions from two inﬂuenza A virus strains (H1N1
nd H3N2) and from the two B lineage strains (Yamagata and
ictoria) [1–3]. Each year, the exact strains to be included in the
uadrivalent and trivalent seasonal inﬂuenza vaccines are deter-
ined by the World Health Organization based on inﬂuenza disease
urveillance data from the previous year [4]. Because the two
nﬂuenza B lineages have co-circulated globally for over a decade,
ersons vaccinated with trivalent inactivated inﬂuenza vaccine
IIV3), which contains only one B strain, have been left unpro-
ected against the B lineage not included in the vaccine [1,2]. IIV4
ffers improved coverage over IIV3 and is expected to substantially
educe illness and hospitalizations due to inﬂuenza B [5,6]. Several
uadrivalent inﬂuenza vaccines have been recently licensed for use
n the US and are either approved or awaiting approval in Europe
3,4]. These vaccines have been consistently shown to be as safe
nd as immunogenic as their trivalent counterparts [7–12].
A recent phase III trial conducted in France during the 2011/2012
nﬂuenza season demonstrated the safety and immunogenicity of
n IIV4 candidate in healthy adults [12]. Here, we report the results
f a phase III trial investigating the safety, immunogenicity, and lot-
o-lot consistency of this IIV4 candidate in children, adolescents,
nd adults, and the ﬁrst results for this vaccine in children and
dolescents.
. Materials and methods
.1. Study design
This was a phase III, randomized, controlled, multicenter trial
n children/adolescents (9 through 17 years of age) and adults (18
hrough 60 years of age) performed at six centers in Australia and
our centers in the Philippines in 2012 (ClinicalTrials.gov iden-
iﬁer: NCT01481454). The study was double-blind for IIV4 lots
nd open-label for IIV4 vs IIV3. The primary objective was  to
escribe the safety proﬁles (injection-site reactions and systemic
vents) of IIV4 and IIV3 during the 21 days following vacci-
ation and the serious adverse events (SAEs) for 6 months in
ll adult and child/adolescent participants. Secondary objectives
ere to demonstrate compliance of IIV4 with European Medicines
gency (EMA) immunogenicity criteria in adults, demonstrate the
mmunogenic consistency of three lots of IIV4, and describe post-
accination seroneutralization titers in children/adolescents. The
tudy was approved by the independent ethics committee and/or
nstitutional review board responsible for each study site and was
arried out in accordance with International Conference on Har-
onization Guidelines for Good Clinical Practice, the Declaration
f Helsinki, and with all national and local ethical requirements.
ritten informed consent was obtained from all adult participants
nd from all parents or legal representatives of 9–17-year-old par-
icipants included in the trial. Some 9–17-year-old participants also
rovided written informed assent where required by local regula-
ions.
.2. Study population
Individuals 9–60 years old who had not been previously
accinated against inﬂuenza with a 2012 Southern Hemisphere
ormulation or a 2011–2012 Northern Hemisphere formulation in
he previous 6 months were considered for study inclusion. They
ere excluded if they had received another vaccination within 4
eeks before inclusion; were allergic to or had a history of a seri-
us adverse reaction (AR) to any inﬂuenza vaccine; had a known orne 33 (2015) 2485–2492
suspected congenital or acquired immunodeﬁciency; had moder-
ate or severe acute illness/infection or a temperature ≥ 38.0 ◦C; or
had recently received immunosuppressive or corticosteroid treat-
ment, immune globulins, blood, or blood-derived products. Women
were excluded if they were pregnant, lactating, or of childbear-
ing potential and not using adequate birth control. Enrollment was
stratiﬁed by age at each site into children/adolescents 9 through 17
years old and adults 18 through 60 years old.
2.3. Randomization
Adult participants were randomized 10:10:10:1 and chil-
dren/adolescents 2:2:2:1 to be immunized with one of three lots of
IIV4 or with licensed IIV3. Participants were randomized using the
permuted block method with stratiﬁcation by site and age group
and were assigned to the treatment groups via an interactive voice
or web response system. All vaccines were administered by intra-
muscular injection with a 16-mm,  25-gauge needle. The study was
open-label for receipt of either IIV4 or licensed IIV3 and was double-
blind for IIV4 lots so that neither the investigator nor the subject
or subject’s legal representative knew which lot was  administered.
Blood samples were collected before vaccination (day 0) and 21
days after vaccination.
2.4. Vaccines
All vaccines were inactivated, split-virion preparations contain-
ing 15 g hemagglutinin per strain in a total volume of 0.5 mL.  IIV4
lot 1 (batch S4361), lot 2 (batch S4362), and lot 3 (batch S4363)
contained the A/California/07/2009 (H1N1), A/Victoria/210/2009
(H3N2), and B/Brisbane/60/2008 (Victoria lineage) strains (which
were among those recommended for the 2011/2012 Northern
Hemisphere and the 2012 Southern Hemisphere formulations), and
the B/Florida/04/2006 strain (Yamagata lineage). The licensed IIV3
(batch H0290) was the 2011/2012 Northern Hemisphere formu-
lation of Vaxigrip® (Sanoﬁ Pasteur, Marcy-l’Étoile, France), which
contained the A/California/07/2009 (H1N1), A/Victoria/210/2009
(H3N2), and B/Brisbane/60/2008 (Victoria lineage) strains.
2.5. Hemagglutination inhibition (HAI) assay
The HAI assay was  performed as previously described [11]. The
highest serum dilution resulting in complete inhibition of hemag-
glutination was determined in duplicate for each sample. The titer
for each strain was calculated as the geometric mean of the recip-
rocal of the duplicate values obtained for each sample. The lower
limit of quantitation was  a titer of 10, which is the reciprocal of the
lowest dilution used in the assay. Samples with HAI antibody titers
below 10 were assigned a titer of 5. The seroprotection rate for each
group was  the percentage of participants with a titer ≥40. The sero-
conversion rate for each group was  the percentage of participants
with either a pre-vaccination titer <10 and a post-vaccination titer
≥40 or a pre-vaccination titer ≥10 and a ≥4-fold increase in titer at
day 21.
2.6. Seroneutralization assay
The seroneutralization assay was a microneutralization assay
based on methods previously described by the World Health
Organization and the US Centers for Disease Control and Pre-
vention [13,14]. Serially diluted, heat-inactivated serum samples
from vaccinated child/adolescent participants were pre-incubated
with a ﬁxed amount of inﬂuenza A or B virus prior to adding the
serum-virus mixture to Madin-Darby canine kidney cell cultures.
After overnight incubation, viral nucleoprotein production in the
infected cells was  measured by enzyme-linked immunosorbent
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ssay using a monoclonal antibody speciﬁc to the nucleoprotein
f either inﬂuenza A or B. Reduced or absent infectivity indicated
he presence of inﬂuenza virus-speciﬁc neutralizing antibodies in
uman sera. The neutralization titer expressed by the reciprocal
1/dilution) was calculated by the intersection of the optical den-
ity curve of the test sample and the 50% neutralization point of the
ontrol optical density curve. The lower limit of quantitation was  a
iter of 10, which was the reciprocal of the lowest dilution used in
he assay. Samples with neutralizing antibody titers below 10 were
ssigned a titer of 5.
.7. Reactogenicity and safety
Solicited injection-site reactions (pain, erythema, swelling,
nduration, ecchymosis) and systemic reactions (fever, headache,
alaise, myalgia, shivering) were recorded for 7 days after each
accination. Unsolicited adverse events (AEs) and SAEs were col-
ected according to the International Committee for Harmonization
uideline for Clinical Safety Data Management: Deﬁnitions and
tandards for Expedited Reporting. Unsolicited AEs were collected
or 21 days after vaccination. Immediate unsolicited adverse reac-
ions (ARs) were those occurring within 30 min  of vaccination and
ere considered to be related to the vaccination. SAEs and AEs
f special interest were collected for 6 months after vaccination.
Es of special interest included anaphylaxis, Guillain-Barré syn-
rome, encephalitis, myelitis, neuritis, convulsions, and vasculitis.
Es and SAEs were classiﬁed by the center investigators as related
r unrelated to the study vaccines.
.8. Sample size determination
A total of 1980 participants (330 children/adolescents and
705 adults) were planned to receive IIV4. This was estimated to
llow AEs with a true incidence of 0.15% overall or 0.90% in chil-
ren/adolescents to be detected with a probability of 95%. Based on
imulations, 660 participants in each IIV4 lot group would provide
0% power to demonstrate lot-to-lot consistency for immunogenic-
ty with an alpha of 5%.
.9. Statistical analysis
Statistical analysis was performed using SAS version 9.2 (SAS
nstitute, Cary, NC). Safety was assessed in all participants who
eceived a study vaccine according to the vaccine received. Lot-to-
ot consistency was assessed in all participants who  completed the
tudy according to protocol. Lot-to-lot equivalence for each strain
as demonstrated if the age group-stratiﬁed two-sided 95% con-
dence interval (CI) of the post-vaccination HAI geometric mean
ntibody titer (GMT) ratio for that strain in the two lots being com-
ared was between 0.67 and 1.5. Age group-stratiﬁed 95% CIs were
alculated using an analysis of variance model (type II analysis)
f log10-transformed titers. The 95% CIs for GMTs and GMT  ratios
HAI and seroneutralization) were calculated from the Student’s t
istribution of log10-transformed titers.
. Results
.1. Study participants
Between March 19, 2012 and April 28, 2012, 1390 participants
n the Philippines and 700 participants in Australia were enrolled
nd randomized (Fig. 1). The last follow-up visit was on October
1, 2012. Of the 2090 participants, 1977 were vaccinated with IIV4
1648 adults and 329 children/adolescents) and 111 with IIV3 (56
dults and 55 children/adolescents). A total of 2071 participants
1962 IIV4, 109 IIV3) completed the study. Sex ratios were nearlyne 33 (2015) 2485–2492 2487
equivalent in the adult IIV3 group and in both child/adolescent
groups, however the adult IIV4 group contained more women
(61.4%) than men  (Supplementary Table 1). Within each age group,
mean ages and inﬂuenza vaccination histories were similar for the
two vaccine groups. Most of the participants in each group were
Asian.
3.2. Reactogenicity and safety
Solicited reaction frequencies were similar for IIV4 and IIV3 in
adults (IIV4: 61.2%, 95% CI [58.8; 63.6]; IIV3: 57.1%, 95% CI [43.2;
70.3]) as well as in children/adolescents (IIV4: 66.6%, 95% CI [61.2;
71.6]; IIV3: 67.3%, 95% CI [53.3; 79.3]) (Fig. 2). Reactogenicity pro-
ﬁles were also similar for the three lots of IIV4 in both age groups
(data not shown). In all groups, pain was the most common solicited
injection-site reaction, whereas headache, malaise, and myalgia
were the most common solicited systemic reactions. Almost all
injection-site (99.1%) and systemic reactions (96.2%) were mild
or moderate in severity and most (88.2%) resolved within 3 days.
Although 19 (1.2%) adult IIV4 recipients reported grade 3 headache
and 16 (1.0%) reported grade 3 malaise, all other types of grade
3 reactions were reported by less than 1% of the IIV4 recipients
in either age group. Less than 2% the IIV3 recipients reported a
grade 3 injection-site reaction and none reported a grade 3 systemic
reaction.
Frequencies of unsolicited AEs were also similar for both vac-
cines in adults (IIV4: 18.0%, 95% CI [16.1; 19.9]; IIV3: 12.5%, 95% CI
[5.2; 24.1]) and in children/adolescents (IIV4: 17.6%, 95% CI [13.7;
22.2]; IIV3: 29.1%, 95% CI [17.6; 42.9]). Unsolicited AEs related to
vaccination in both age groups were reported for less than 4% of
IIV4 recipients (59/1648 adults, 6/329 children/adolescents) and
less than 10% of IIV3 recipients (7/56 adults, 5/55 children adoles-
cents). An unsolicited immediate AR (within 30 min) was reported
by one adult in the IIV4 group (urticaria) and one adult in the IIV3
group (cough). Both resolved within 2 days and both participants
completed the study. The most frequently reported unsolicited AE
related to vaccination was  injection-site pruritus, which occurred
in 13 adults (0.8%) and one child/adolescent (0.3%) vaccinated with
IIV4 and in one child/adolescent (1.8%) vaccinated with IIV3. Grade
3 vaccine-related ARs were reported for 4 adults in the IIV4 group
(0.2%): 3 had tremors, dizziness, or cough that resolved in 2 days
or less and 1 had fatigue that resolved within 4 days. A total of 13
SAEs were reported during the 6-month study period; all occurred
in IIV4 recipients (12 adults and one child/adolescent) and none
were considered to be vaccine-related. No participants discontin-
ued the study due to an AE and no AEs of special interest or deaths
were reported during the study.
3.3. Immunogenicity
Within each age group, prevaccination HAI antibody titers were
similar for participants receiving IIV3 and IIV4, and both vaccines
increased HAI antibody titers by post-vaccination day 21 (Fig. 3).
For the three strains common to both vaccines (A/H1N1, A/H3N2,
and B/Brisbane), within each age group, post-vaccination HAI anti-
body responses induced by IIV4 were comparable to the responses
induced by IIV3. In adults, mean GMTs for these three strains
increased 7.3- to 10.0-fold with IIV4 and 6.6- and 9.3-fold with IIV3.
In children/adolescents, GMTs increased 7.5- to 23.4-fold with IIV4
and 6.4- to 16.6-fold with IIV3. As expected for the IIV4-speciﬁc
B/Florida strain, GMTs increased to a greater extent with IIV4 than
with IIV3, both in adults (8.4-fold for IIV4 vs 3.2-fold for IIV3) and in
children/adolescents (19.4-fold for IIV4 vs 3.8-fold for IIV3). Over-
all, post-vaccination GMTs for all 4 strains were at least as high in
children/adolescents as in adults.
2488 J.B. Cadorna-Carlos et al. / Vaccine 33 (2015) 2485–2492
Fig. 1. Participant disposition. Adults (18–60 y) and children/adolescents (child/adols, 9–17 y) were enrolled and then randomized to receive one of three lots of IIV4 or IIV3.
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rwo  participants withdrew prior to vaccination. Following vaccination, 4 participan
f  the remaining participants had protocol violations and were removed from the Pe
nﬂuenza vaccine.
IIV4 met  all EMA  criteria for adult vaccine recipients. In adults,
ost-vaccination seroprotection rates were ≥ 99%, seroconver-
ion rates were >59%, and post-vaccination/pre-vaccination GMT
atios were ≥7.3 for all four vaccine strains (Table 1). In addi-
ion, the lower limits of the 95% CIs for these values exceeded
MA criteria. Although there are no EMA  criteria for children
r adolescents, in these participants, post-vaccination seropro-
ection rates were >98%, seroconversion rates were >61%, and
ost-vaccination/pre-vaccination GMT  ratios were ≥7.5 for all four
trains (Table 1).
Lot-to-lot equivalence was demonstrated for all three lots of IIV4
or all four strains (Table 2, Supplementary Fig. 1). The ratios of the
verall post-vaccination GMTs for each pair of lots for each strain
ere between 0.82 and 1.10, and the 95% CIs for these GMT  ratios
ere all between 0.67 and 1.5.
Seroneutralization titers for the three stains common to IIV3 and
IV4 (A/H1N1, A/H3N2, and B/Brisbane) were similar for the two
hildren/adolescent vaccine groups (Supplementary Table 2). Like
he HAI titers, seroneutralization responses for the B/Florida strain
ere substantially higher in the IIV4 group (26.5-fold increase) than
n the IIV3 group (3.7-fold increase).
. DiscussionDifﬁculties in predicting the global circulation of inﬂuenza
 viruses have resulted in missed opportunities for protec-
ion. Because quadrivalent inﬂuenza vaccines induce antibody
esponses against both inﬂuenza B lineages, they offer broaderre withdrawn due to noncompliance (NC) or were lost to follow-up (LFU). Thirteen
ocol Set. IIV3, trivalent inactivated inﬂuenza vaccine; IIV4, quadrivalent inactivated
protection than trivalent inﬂuenza vaccines. This study found com-
parable reactogenicity and safety proﬁles for the IIV4 candidate
and IIV3 in both adults and in children/adolescents. The study also
showed that the immunogenicity of three lots of IIV4 was equiva-
lent for all four strains.
Both vaccines were well tolerated by both age groups. Most
solicited injection-site and systemic reactions with either vaccine
were mild to moderate and most resolved within a few days.
Although no grade 3 systemic reactions were reported for IIV3
(small sample size), a few were reported for IIV4. The most fre-
quent of these was headache in adult IIV4 recipients (1.2%). All other
grade 3 systemic reactions (fever, malaise, myalgia, and shivering)
were reported by ≤1% of the IIV4 recipients in either age group.
Similar ﬁndings in adults have been reported previously for IIV4
[7,11,12]. Frequencies of unsolicited AEs in the 21 days following
vaccination were similar in adults and in children/adolescents vac-
cinated with IIV4 and few of these were considered to be treatment
related.
Together with the previous phase III study [12], 328 chil-
dren/adolescents, 2423 adults 18–60 years of age, and 784 older
adults have now been vaccinated with the IIV4 candidate, for a total
of 3525 recipients. This number of vaccinated participants should
allow AEs with a true incidence of 0.085% overall to be observed
with a probability of 95%. Among all IIV4 vaccinees, no participants
have discontinued a study due to an AE and no vaccine-related
SAEs, no AEs of special interest, and no safety issues or concerns
have been reported. These two clinical trials demonstrate that the
addition of a second B strain to IIV3 does not affect its safety,
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Fig. 2. Solicited injection-site and systemic reactions. The percentages of participants reporting any solicited reaction and speciﬁc solicited reactions are shown for adults
(A)  and for children/adolescents (B). Results are for the Safety Analysis Set that included all participants who  received a study vaccine. Erythema, swelling, induration, and
ecchymosis in children 9–11 years old were considered grade 1 if >0 to <25 mm,  grade 2 if ≥25 to <50 mm,  and grade 3 if ≥50 mm;  in participants 12–60 years old, they were
considered grade 1 if ≥25 to ≤50 mm,  grade 2 if ≥51 to ≤100 mm,  and grade 3 if >100 mm.  Fever was  considered grade 1 if ≥38.0 ◦C to ≤38.4 ◦C, grade 2 if ≥38.5 ◦C to ≤38.9 ◦C,
and  grade 3 if ≥39.0 ◦C. Pain in children 9–11 years old was  considered grade 1 if easily tolerated, grade 2 if sufﬁciently discomforting to interfere with normal behavior or
activities, and grade 3 if incapacitating and preventing performance of usual activities. Pain in subjects 12–60 years old and all other events in all age groups were considered
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nﬂuenza vaccine; IIV4, quadrivalent inactivated inﬂuenza vaccine. *The “Any” categ
ystemic reaction and the percentage reporting any grade 3 reaction. Grade 1 and 2
hich agrees with reports for other quadrivalent inactivated and
ive-attenuated vaccines [8–11].
IIV4 vaccination induced robust antibody responses for all four
trains in both age groups. The antibody responses were similar
able 1
emagglutination inhibition immunogenicity of IIV4.
Measure EMA  requirement A/H1N1 
Adults (18 − 60 y)
Post-vaccination (day 21)
seroprotectiona rate
>70% 99.3 (98.7, 99.6) 
Post-vaccination (day 21) to
pre-vaccination (day 0) GMT ratiob
>2.5 9.2 (8.5, 10.0) 
Rate  of seroconversionc or signiﬁcant
increased
>40% 63.6 (61.2, 65.9) 
Children/adolescents (9–17 y)
Post-vaccination (day 21)
seroprotectiona rate
– 98.8 (96.9; 99.7) 
Post-vaccination (day 21) to
pre-vaccination (day 0) GMT ratiob
– 12.0 (10.2; 14.0) 
Rate  of seroconversionc or signiﬁcant
increased
– 77.7 (72.8; 82.1) 
alues are for the Other Analysis Set, which included randomized participants who re
uadrivalent inactivated inﬂuenza vaccine.
a Seroprotection is deﬁned as a HAI titer ≥40; values are the percent of participants in 
b Values are the geometric means of the individual post-vaccination (day 21) HAI titer/p
n  each group.
c Seroconversion is deﬁned as a pre-vaccination (day 0) HAI titer <10 and post-vaccina
d Signiﬁcant increase is deﬁned as a pre-vaccination (day 0) HAI titer ≥10 and post-vacc
ercent of participants in each group (with 95% CIs in brackets) who  either seroconvertedd grade 3 for signiﬁcant and preventing daily activities. IIV3, trivalent inactivated
hows the overall percentage of participants reporting any solicited injection-site or
ions are not shown for this category.
to those induced by IIV3 for the three strains in common and
were higher with IIV4 for the B/Florida strain that was not in
IIV3. In addition, IIV4 met  all adult EMA  immunogenicity criteria
for seroprotection rates, GMT  ratios, and seroconversion rates for
A/H3N2 B/Brisbane B/Florida
99.0 (98.4, 99.4) 100.0 (99.8, 100.0) 100.0 (99.8, 100.0)
7.3 (6.8, 7.9) 10.0 (9.2, 10.8) 8.4 (7.8, 9.0)
59.3 (56.8, 61.7) 66.5 (64.2, 68.8) 65.9 (63.5, 68.1)
100.0 (98.9; 100.0) 99.4 (97.8; 99.9) 99.4 (97.8; 99.9)
7.5 (6.3; 8.9) 23.4 (19.6; 27.8) 19.4 (16.3; 23.2)
61.8 (56.3; 67.1) 83.8 (79.3; 87.6) 84.8 (80.4; 88.5)
ceived one dose of IIV4 and had valid pre- and post-vaccination HAI titers. IIV4,
each group (with 95% CIs in brackets) with a HAI titer ≥40.
re-vaccination (day 0) HAI titer ratios (with 95% CIs in brackets) for the participants
tion (day 21) HAI titer ≥40.
ination (day 21) HAI titer/pre-vaccination (day 0) HAI titer ratio ≥4. Values are the
 or had a signiﬁcant increase in HAI titer.
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Fig. 3. Geometric mean HAI titers for IIV4 and IIV3. HAI titers were measured on day 0 (pre-vaccination) and 21 days post-vaccination. Bars indicate the geometric mean
titers  (GMTs) in adults (A) and adolescents/children (B), and whiskers indicate the 95% C
received a study vaccine and had a valid post-vaccination titer result. IIV4, quadrivalent i
Table 2
IIV4 lot-to-lot comparisons.
Strain Comparison GMT  ratio (95% CI) Equivalence
A/H1N1 Lot 1 vs Lot 2 1.10 (0.97; 1.24) Yes
Lot 1 vs Lot 3 0.89 (0.79; 1.01) Yes
Lot 2 vs Lot 3 0.82 (0.72; 0.92) Yes
A/H3N2 Lot 1 vs Lot 2 1.01 (0.90; 1.14) Yes
Lot 1 vs Lot 3 0.91 (0.81; 1.03) Yes
Lot 2 vs Lot 3 0.90 (0.80; 1.02) Yes
B/Brisbane Lot 1 vs Lot 2 1.00 (0.89; 1.12) Yes
Lot 1 vs Lot 3 1.00 (0.89; 1.13) Yes
Lot 2 vs Lot 3 1.00 (0.89; 1.13) Yes
B/Florida Lot 1 vs Lot 2 0.98 (0.88; 1.10) Yes
Lot 1 vs Lot 3 0.95 (0.86; 1.06) Yes
Lot 2 vs Lot 3 0.97 (0.87; 1.08) Yes
Values are for the Per Protocol Set, which included randomized participants who
completed the study according to protocol. The age-stratiﬁed GMTs for each strain
for  each lot are shown in Supplementary Fig. 1. GMT, geometric mean HAI titer. Lot-
to-lot equivalence for each strain was demonstrated if the two-sided 95% conﬁdence
interval (CI) of the post-vaccination ratio of the overall GMTs for that strain in the
two  lots being compared was  between 0.67 and 1.5.Is. Results shown are for the Full Analysis Set, which included all participants who
nactivated inﬂuenza vaccine; IIV3, trivalent inactivated inﬂuenza vaccine.
all four strains. Although there are currently no EMA  criteria for
children or adolescents, IIV4 responses tended to be higher in chil-
dren/adolescents than in adults. These results suggest that a single
dose of IIV4 provides sufﬁcient immunity for adults and for children
as young as 9 years old.
Although high HAI antibody titers generally correlate with pro-
tection for adults [15,16], the correlation is weaker in elderly adults
[17,18] and in young children, the latter of which were shown to
require HAI titers >110 to achieve 50% protection [19]. In addition,
live-attenuated inﬂuenza vaccines are effective in young children
but do not produce high HAI titers [20]. Hence, alternative sero-
logical assays are under evaluation to identify other protection
correlates. Seroneutralization assays measure the capacity of all
antibodies in the serum to neutralize live inﬂuenza viruses and
have the potential to be more sensitive than HAI assays, which
measure antibodies against only one viral protein [21–24]. Our
microneutralization assay is based on enzyme immunoassay of
viral nucleoprotein rather than on cytopathic effect. Although this
assay was  originally developed for use with pandemic inﬂuenza
viruses (e.g. A/H5N1 and A/H1N1) [13,14], it is now frequently used
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o measure responses to other human inﬂuenza A and B viruses
7,25,26]. The assay is strain-speciﬁc, highly sensitive, and requires
ess time than neutralization assays based on cytopathic effect and
he results have been shown to correlate with HAI [25]. IIV4 and
IV3 both increased seroneutralization antibody titers substantially
n children/adolescents with patterns similar to the HAI assay for
ach strain. This assay should be studied as an alternative measure
f immunogenicity in future clinical trials.
The results of our study are in accordance with the previous
hase III trial assessing this IIV4 candidate [12] and with several
ther clinical trials [7–11], which have shown that quadrivalent
accines are as immunogenic as their trivalent counterparts for the
atched inﬂuenza strains and that the two vaccine formulations
ave comparable safety proﬁles. Thus, the addition of a second B
train to a licensed trivalent vaccine offers additional protection
gainst inﬂuenza B, does not interfere with the immunogenicity of
he three shared strains, and has little, if any, impact on vaccine
afety or reactogenicity.
This was a large study sufﬁciently powered to observe infre-
uent AEs and to conﬁrm lot-to-lot equivalence. Because we
ocused on these objectives for the adult IIV4 group, the other
roups in our study were too small to permit other statistically
eliable comparisons. Thus, the study did not allow assessment
f non-inferiority or superiority of the IIV4 responses to IIV3 nor
omparisons between age groups.
In conclusion, this study demonstrated that IIV4 can be
eproducibly manufactured to yield a well-tolerated, safe, and
mmunogenic vaccine in persons 9–60 years of age and that it met
ll EMA immunogenicity criteria in adults. Vaccination with this
IV4 candidate rather than IIV3 offers a broader immune response
o inﬂuenza B and might help reduce inﬂuenza-related hospitaliza-
ions, costs, and deaths.
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